{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:05:32Z","timestamp":1792195532913,"version":"4.4.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/nbt.2725","type":"journal-article","created":{"date-parts":[[2013,10,20]],"date-time":"2013-10-20T20:33:36Z","timestamp":1382301216000},"page":"999-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":198,"title":["Reassessing target antigens for adoptive T-cell therapy"],"prefix":"10.1038","volume":"31","author":[{"given":"Christian S","family":"Hinrichs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P","family":"Restifo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"key":"BFnbt2725_CR1","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever, M.A. et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323\u20135337 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnbt2725_CR2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S.A., Yang, J.C. & Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909\u2013915 (2004).","journal-title":"Nat. Med."},{"key":"BFnbt2725_CR3","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S.A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnbt2725_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P.F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnbt2725_CR5","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer, J.N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709\u20132720 (2012).","journal-title":"Blood"},{"key":"BFnbt2725_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop, H.E. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925\u2013935 (2010).","journal-title":"Blood"},{"key":"BFnbt2725_CR7","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1172\/JCI32205","volume":"117","author":"CM Paulos","year":"2007","unstructured":"Paulos, C.M. et al. Microbial translocation augments the function of adoptively transferred self\/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197\u20132204 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnbt2725_CR8","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","volume":"174","author":"PA Antony","year":"2005","unstructured":"Antony, P.A. et al. CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591\u20132601 (2005).","journal-title":"J. Immunol."},{"key":"BFnbt2725_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907\u2013912 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnbt2725_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L.A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"BFnbt2725_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M.R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).","journal-title":"Mol. Ther."},{"key":"BFnbt2725_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan, R.A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133\u2013151 (2013).","journal-title":"J. Immunother."},{"key":"BFnbt2725_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R.A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"BFnbt2725_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G.P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"BFnbt2725_CR15","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron, B.J. et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnbt2725_CR16","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.4049\/jimmunol.173.12.7209","volume":"173","author":"DC Palmer","year":"2004","unstructured":"Palmer, D.C. et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 173, 7209\u20137216 (2004).","journal-title":"J. Immunol."},{"key":"BFnbt2725_CR17","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.1073\/pnas.0710929105","volume":"105","author":"DC Palmer","year":"2008","unstructured":"Palmer, D.C. et al. Effective tumor treatment targeting a melanoma\/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl. Acad. Sci. USA 105, 8061\u20138066 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2725_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1084\/jem.20030590","volume":"198","author":"WW Overwijk","year":"2003","unstructured":"Overwijk, W.W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569\u2013580 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnbt2725_CR19","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1200\/JCO.2007.12.1087","volume":"25","author":"BC Leibovich","year":"2007","unstructured":"Leibovich, B.C. et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol. 25, 4757\u20134764 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnbt2725_CR20","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2008.17.6073","volume":"26","author":"AH Brouwers","year":"2008","unstructured":"Brouwers, A.H., Mulders, P.F.A. & Oyen, W.J.G. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. J. Clin. Oncol. 26, 3808\u20133809, author reply 3811\u20133812 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnbt2725_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0002-9440(10)64038-2","volume":"158","author":"S Ivanov","year":"2001","unstructured":"Ivanov, S. et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158, 905\u2013919 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnbt2725_CR22","doi-asserted-by":"publisher","first-page":"6540","DOI":"10.1200\/JCO.2005.07.732","volume":"23","author":"AH Brouwers","year":"2005","unstructured":"Brouwers, A.H. et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J. Clin. Oncol. 23, 6540\u20136548 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnbt2725_CR23","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CHJ Lamers","year":"2006","unstructured":"Lamers, C.H.J. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20\u2013e22 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnbt2725_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers, C.H. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904\u2013912 (2013).","journal-title":"Mol. Ther."},{"key":"BFnbt2725_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/scbi.1998.0119","volume":"9","author":"S Hammarstr\u00f6m","year":"1999","unstructured":"Hammarstr\u00f6m, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67\u201381 (1999).","journal-title":"Semin. Cancer Biol."},{"key":"BFnbt2725_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen, M. et al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 28, 1248\u20131250 (2010).","journal-title":"Nat. Biotechnol."},{"key":"BFnbt2725_CR27","doi-asserted-by":"publisher","first-page":"D1011","DOI":"10.1093\/nar\/gkq1259","volume":"39","author":"MN McCall","year":"2011","unstructured":"McCall, M.N., Uppal, K., Jaffee, H.A., Zilliox, M.J. & Irizarry, R.A. The Gene Expression Barcode: leveraging public data repositories to begin cataloging the human and murine transcriptomes. Nucleic Acids Res. 39, D1011\u2013D1015 (2011).","journal-title":"Nucleic Acids Res."},{"key":"BFnbt2725_CR28","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","volume":"14","author":"JL Gulley","year":"2008","unstructured":"Gulley, J.L. et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14, 3060\u20133069 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnbt2725_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/JCO.2005.10.206","volume":"23","author":"JL Marshall","year":"2005","unstructured":"Marshall, J.L. et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23, 720\u2013731 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnbt2725_CR30","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1158\/1078-0432.CCR-03-0706","volume":"10","author":"GJ Ullenhag","year":"2004","unstructured":"Ullenhag, G.J. et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte\/macrophage colony-stimulating factor. Clin. Cancer Res. 10, 3273\u20133281 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnbt2725_CR31","doi-asserted-by":"publisher","first-page":"8446","DOI":"10.1158\/0008-5472.CAN-08-1864","volume":"68","author":"R Bos","year":"2008","unstructured":"Bos, R. et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 68, 8446\u20138455 (2008).","journal-title":"Cancer Res."},{"key":"BFnbt2725_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ijc.2910450314","volume":"45","author":"PG Natali","year":"1990","unstructured":"Natali, P.G. et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer 45, 457\u2013461 (1990).","journal-title":"Int. J. Cancer"},{"key":"BFnbt2725_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0198-8859(97)00255-3","volume":"59","author":"I Kawashima","year":"1998","unstructured":"Kawashima, I. et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59, 1\u201314 (1998).","journal-title":"Hum. Immunol."},{"key":"BFnbt2725_CR34","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S1470-2045(09)70315-8","volume":"10","author":"KL Jones","year":"2009","unstructured":"Jones, K.L. & Buzdar, A.U. Evolving novel anti-HER2 strategies. Lancet Oncol. 10, 1179\u20131187 (2009).","journal-title":"Lancet Oncol."},{"key":"BFnbt2725_CR35","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1073\/pnas.0707140104","volume":"105","author":"D Atanackovic","year":"2008","unstructured":"Atanackovic, D. et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl. Acad. Sci. USA 105, 1650\u20131655 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2725_CR36","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1200\/JCO.2005.08.375","volume":"23","author":"N van Baren","year":"2005","unstructured":"van Baren, N. et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23, 9008\u20139021 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnbt2725_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4049\/jimmunol.1001775","volume":"186","author":"N Chinnasamy","year":"2011","unstructured":"Chinnasamy, N. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186, 685\u2013696 (2011).","journal-title":"J. Immunol."},{"key":"BFnbt2725_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","volume":"71","author":"FM Uckun","year":"1988","unstructured":"Uckun, F.M. et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71, 13\u201329 (1988).","journal-title":"Blood"},{"key":"BFnbt2725_CR39","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J.N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"BFnbt2725_CR40","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S.A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2725_CR41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2725_CR42","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnbt2725_CR43","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R.J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnbt2725_CR44","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens, R.J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817\u20134828 (2011).","journal-title":"Blood"},{"key":"BFnbt2725_CR45","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00262-011-1009-3","volume":"60","author":"LD Anderson","year":"2011","unstructured":"Anderson, L.D. et al. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol. Immunother. 60, 985\u2013997 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnbt2725_CR46","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1158\/1078-0432.CCR-13-0168","volume":"19","author":"MV Maus","year":"2013","unstructured":"Maus, M.V. & June, C.H. Zoom zoom: racing CARs for multiple myeloma. Clin. Cancer Res. 19, 1917\u20131919 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnbt2725_CR47","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R.O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnbt2725_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/01.cji.0000177999.95831.7b","volume":"28","author":"CS Hinrichs","year":"2005","unstructured":"Hinrichs, C.S., Palmer, D.C., Rosenberg, S.A. & Restifo, N.P. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J. Immunother. 28, 517\u2013524 (2005).","journal-title":"J. Immunother."},{"key":"BFnbt2725_CR49","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2725_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71\u201375 (2013).","journal-title":"Nat. Biotechnol."},{"key":"BFnbt2725_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nbt.2471","volume":"31","author":"K Hanada","year":"2013","unstructured":"Hanada, K. & Restifo, N.P. Double or nothing on cancer immunotherapy. Nat. Biotechnol. 31, 33\u201334 (2013).","journal-title":"Nat. Biotechnol."},{"key":"BFnbt2725_CR52","doi-asserted-by":"publisher","first-page":"17469","DOI":"10.1073\/pnas.0907448106","volume":"106","author":"CS Hinrichs","year":"2009","unstructured":"Hinrichs, C.S. et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106, 17469\u201317474 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2725_CR53","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1182\/blood-2009-02-203935","volume":"114","author":"CS Hinrichs","year":"2009","unstructured":"Hinrichs, C.S. et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114, 596\u2013599 (2009).","journal-title":"Blood"},{"key":"BFnbt2725_CR54","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood-2010-05-286286","volume":"117","author":"CS Hinrichs","year":"2011","unstructured":"Hinrichs, C.S. et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808\u2013814 (2011).","journal-title":"Blood"},{"key":"BFnbt2725_CR55","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","volume":"121","author":"SP Kerkar","year":"2011","unstructured":"Kerkar, S.P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746\u20134757 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnbt2725_CR56","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.immuni.2011.09.019","volume":"35","author":"P Muranski","year":"2011","unstructured":"Muranski, P. et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35, 972\u2013985 (2011).","journal-title":"Immunity"},{"key":"BFnbt2725_CR57","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"BFnbt2725_CR58","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1073\/pnas.1221609110","volume":"110","author":"S Zhong","year":"2013","unstructured":"Zhong, S. et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl. Acad. Sci. USA 110, 6973\u20136978 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2725_CR59","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1089\/hum.2008.083","volume":"19","author":"MR Theoret","year":"2008","unstructured":"Theoret, M.R. et al. Relationship of p53 overexpression on cancers and recognition by Anti-p53 T cell receptor-transduced T cells. Hum. Gene Ther. 19, 1219\u20131231 (2008).","journal-title":"Hum. Gene Ther."},{"key":"BFnbt2725_CR60","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/gb-2009-10-11-r130","volume":"10","author":"C Wu","year":"2009","unstructured":"Wu, C. et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 10, R130 (2009).","journal-title":"Genome Biol."},{"key":"BFnbt2725_CR61","first-page":"472","volume":"71","author":"GR Grubb","year":"1994","unstructured":"Grubb, G.R., Yun, K., Williams, B.R., Eccles, M.R. & Reeve, A.E. Expression of WT1 protein in fetal kidneys and Wilms tumors. Lab. Investig. 71, 472\u2013479 (1994).","journal-title":"Lab. Investig."},{"key":"BFnbt2725_CR62","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1242\/dev.119.4.1329","volume":"119","author":"S Mundlos","year":"1993","unstructured":"Mundlos, S. et al. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 119, 1329\u20131341 (1993).","journal-title":"Development"},{"key":"BFnbt2725_CR63","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/(SICI)1096-9896(199606)179:2<162::AID-PATH545>3.0.CO;2-0","volume":"179","author":"P Ramani","year":"1996","unstructured":"Ramani, P. & Cowell, J.K. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours. J. Pathol. 179, 162\u2013168 (1996).","journal-title":"J. Pathol."},{"key":"BFnbt2725_CR64","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1182\/blood.V89.4.1405","volume":"89","author":"K Inoue","year":"1997","unstructured":"Inoue, K. et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405\u20131412 (1997).","journal-title":"Blood"},{"key":"BFnbt2725_CR65","doi-asserted-by":"publisher","first-page":"174ra27","DOI":"10.1126\/scitranslmed.3004916","volume":"5","author":"AG Chapuis","year":"2013","unstructured":"Chapuis, A.G. et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 5, 174ra27 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnbt2725_CR66","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/030089169708300301","volume":"83","author":"E Seregni","year":"1997","unstructured":"Seregni, E. et al. Structure, function and gene expression of epithelial mucins. Tumori 83, 625\u2013632 (1997).","journal-title":"Tumori"},{"key":"BFnbt2725_CR67","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1177\/002215549704501111","volume":"45","author":"Y Cao","year":"1997","unstructured":"Cao, Y. et al. Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterogeneous tumor-associated aberrations in glycosylation. J. Histochem. Cytochem. 45, 1547\u20131557 (1997).","journal-title":"J. Histochem. Cytochem."},{"key":"BFnbt2725_CR68","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.4049\/jimmunol.168.4.1717","volume":"168","author":"M Ayyoub","year":"2002","unstructured":"Ayyoub, M. et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168, 1717\u20131722 (2002).","journal-title":"J. Immunol."},{"key":"BFnbt2725_CR69","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.174.7.4415","volume":"174","author":"Y Zhao","year":"2005","unstructured":"Zhao, Y. et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174, 4415\u20134423 (2005).","journal-title":"J. Immunol."},{"key":"BFnbt2725_CR70","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1007\/s00262-005-0705-2","volume":"54","author":"S Ottaviani","year":"2005","unstructured":"Ottaviani, S., Zhang, Y., Boon, T. & van der Bruggen, P.A. MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol. Immunother. 54, 1214\u20131220 (2005).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnbt2725_CR71","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165\u20131174 (2013).","journal-title":"Blood"},{"key":"BFnbt2725_CR72","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/ijc.2910410303","volume":"41","author":"P Hersey","year":"1988","unstructured":"Hersey, P., Jamal, O., Henderson, C., Zardawi, I. & D'Alessandro, G. Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma. Int. J. Cancer 41, 336\u2013343 (1988).","journal-title":"Int. J. Cancer"},{"key":"BFnbt2725_CR73","doi-asserted-by":"publisher","first-page":"e25220","DOI":"10.1371\/journal.pone.0025220","volume":"6","author":"N Alvarez-Rueda","year":"2011","unstructured":"Alvarez-Rueda, N. et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS ONE 6, e25220 (2011).","journal-title":"PLoS ONE"},{"key":"BFnbt2725_CR74","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0940-2993(11)80218-6","volume":"44","author":"HD Mennel","year":"1992","unstructured":"Mennel, H.D. et al. Expression of GD2-epitopes in human intracranial tumors and normal brain. Exp. Toxicol. Pathol. 44, 317\u2013324 (1992).","journal-title":"Exp. Toxicol. Pathol."},{"key":"BFnbt2725_CR75","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis, C.U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050\u20136056 (2011).","journal-title":"Blood"},{"key":"BFnbt2725_CR76","doi-asserted-by":"publisher","first-page":"9437","DOI":"10.1073\/pnas.160270597","volume":"97","author":"CD Wolfgang","year":"2000","unstructured":"Wolfgang, C.D., Essand, M., Vincent, J.J., Lee, B. & Pastan, I. TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc. Natl. Acad. Sci. USA 97, 9437\u20139442 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2725_CR77","doi-asserted-by":"publisher","first-page":"15877","DOI":"10.1073\/pnas.1209042109","volume":"109","author":"V Hillerdal","year":"2012","unstructured":"Hillerdal, V., Nilsson, B., Carlsson, B., Eriksson, F. & Essand, M. T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells. Proc. Natl. Acad. Sci. USA 109, 15877\u201315881 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2725_CR78","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","volume":"290","author":"MGNR Kris","year":"2003","unstructured":"Kris, M.G.N.R. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non\u2013small cell lung cancer: a randomized trial. J. Am. Med. Assoc. 290, 2149\u20132158 (2003).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnbt2725_CR79","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"DG Savage","year":"2002","unstructured":"Savage, D.G. & Antman, K.H. Imatinib mesylate\u2014a new oral targeted therapy. N. Engl. J. Med. 346, 683\u2013693 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2725_CR80","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer. N. Engl. J. Med. 363, 1693\u20131703 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2725_CR81","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2725_CR82","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.humimm.2009.12.007","volume":"71","author":"RL Warren","year":"2010","unstructured":"Warren, R.L. & Holt, R.A. A census of predicted mutational epitopes suitable for immunologic cancer control. Hum. Immunol. 71, 245\u2013254 (2010).","journal-title":"Hum. Immunol."},{"key":"BFnbt2725_CR83","unstructured":"American Cancer Society. Cancer Facts & Figures 2013 http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-036845.pdf (ACA, 2013)."},{"key":"BFnbt2725_CR84","doi-asserted-by":"publisher","first-page":"D652","DOI":"10.1093\/nar\/gkp995","volume":"38","author":"SA Forbes","year":"2010","unstructured":"Forbes, S.A. et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652\u2013D657 (2010).","journal-title":"Nucleic Acids Res."},{"key":"BFnbt2725_CR85","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins, P.F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747\u2013752 (2013).","journal-title":"Nat. Med."},{"key":"BFnbt2725_CR86","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo, N.P., Dudley, M.E. & Rosenberg, S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269\u2013281 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnbt2725_CR87","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter, G.G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838\u20131847 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt2725_CR88","doi-asserted-by":"publisher","first-page":"29608","DOI":"10.1074\/jbc.M110.126722","volume":"285","author":"AB Riemer","year":"2010","unstructured":"Riemer, A.B. et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J. Biol. Chem. 285, 29608\u201329622 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFnbt2725_CR89","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.4049\/jimmunol.167.9.5420","volume":"167","author":"M Evans","year":"2001","unstructured":"Evans, M. et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 167, 5420\u20135428 (2001).","journal-title":"J. Immunol."},{"key":"BFnbt2725_CR90","doi-asserted-by":"crossref","unstructured":"Anonymous. Do no harm. Nat. Biotechnol. 31, 365 (2013).","DOI":"10.1038\/nbt.2587"},{"key":"BFnbt2725_CR91","doi-asserted-by":"publisher","first-page":"20422","DOI":"10.1073\/pnas.0810777105","volume":"105","author":"O Hofmann","year":"2008","unstructured":"Hofmann, O. et al. Genome-wide analysis of cancer\/testis gene expression. Proc. Natl. Acad. Sci. USA 105, 20422\u201320427 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt2725_CR92","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver, D.A., Pellicer, I., Fair, W.R., Heston, W.D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81\u201385 (1997).","journal-title":"Clin. Cancer Res."},{"key":"BFnbt2725_CR93","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1","volume":"73","author":"S Zhang","year":"1997","unstructured":"Zhang, S. et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 73, 42\u201349 (1997).","journal-title":"Int. J. Cancer"},{"key":"BFnbt2725_CR94","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-510X(97)05390-2","volume":"149","author":"N Yuki","year":"1997","unstructured":"Yuki, N., Yamada, M., Tagawa, Y., Takahashi, H. & Handa, S. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J. Neurol. Sci. 149, 127\u2013130 (1997).","journal-title":"J. Neurol. Sci."},{"key":"BFnbt2725_CR95","doi-asserted-by":"crossref","first-page":"21193","DOI":"10.1016\/S0021-9258(19)36816-4","volume":"267","author":"AB Sturrock","year":"1992","unstructured":"Sturrock, A.B. et al. Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener's granulomatosis autoantigen. J. Biol. Chem. 267, 21193\u201321199 (1992).","journal-title":"J. Biol. Chem."},{"key":"BFnbt2725_CR96","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1600-0749.1993.tb00622.x","volume":"6","author":"Z Abattyani","year":"1993","unstructured":"Abattyani, Z., Xerri, L., Hassoun, J., Bonerandi, J.J. & Grob, J.J. Tyrosinase gene expression in human tissues. Pigment Cell Res. 6, 400\u2013405 (1993).","journal-title":"Pigment Cell Res."},{"key":"BFnbt2725_CR97","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1535-7163.MCT-05-0375","volume":"5","author":"S Fukuda","year":"2006","unstructured":"Fukuda, S. & Pelus, L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 5, 1087\u20131098 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"BFnbt2725_CR98","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0022-5347(01)65883-X","volume":"156","author":"AA Elgamal","year":"1996","unstructured":"Elgamal, A.A. et al. Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J. Urol. 156, 464\u2013468 (1996).","journal-title":"J. Urol."},{"key":"BFnbt2725_CR99","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/jjco\/28.12.723","volume":"28","author":"T Ishikawa","year":"1998","unstructured":"Ishikawa, T. et al. Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction. Jpn. J. Clin. Oncol. 28, 723\u2013728 (1998).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"BFnbt2725_CR100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.neo.7900134","volume":"3","author":"E Hiyama","year":"2001","unstructured":"Hiyama, E., Hiyama, K., Yokoyama, T. & Shay, J.W. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 3, 17\u201326 (2001).","journal-title":"Neoplasia"},{"key":"BFnbt2725_CR101","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.4049\/jimmunol.155.8.3711","volume":"155","author":"K Hiyama","year":"1995","unstructured":"Hiyama, K. et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155, 3711\u20133715 (1995).","journal-title":"J. Immunol."},{"key":"BFnbt2725_CR102","first-page":"453","volume":"9","author":"E Hiyama","year":"1996","unstructured":"Hiyama, E. et al. Telomerase activity in human intestine. Int. J. Oncol. 9, 453\u2013458 (1996).","journal-title":"Int. J. Oncol."},{"key":"BFnbt2725_CR103","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0959-8049(97)00062-2","volume":"33","author":"JW Shay","year":"1997","unstructured":"Shay, J.W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787\u2013791 (1997).","journal-title":"Eur. J. Cancer"},{"key":"BFnbt2725_CR104","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/1523-1747.ep12345811","volume":"106","author":"RS Taylor","year":"1996","unstructured":"Taylor, R.S. et al. Detection of telomerase activity in malignant and nonmalignant skin conditions. J. Invest. Dermatol. 106, 759\u2013765 (1996).","journal-title":"J. Invest. Dermatol."},{"key":"BFnbt2725_CR105","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1126\/science.2825356","volume":"238","author":"H Hirai","year":"1987","unstructured":"Hirai, H., Maru, Y., Hagiwara, K., Nishida, J. & Takaku, F. A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238, 1717\u20131720 (1987).","journal-title":"Science"},{"key":"BFnbt2725_CR106","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3279","volume":"12","author":"AK Sewell","year":"2012","unstructured":"Sewell, A.K. Why must T cells be cross-reactive? Nat. Rev. Immunol. 12, 669\u2013677 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnbt2725_CR107","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1096\/fasebj.12.13.1255","volume":"12","author":"MBA Oldstone","year":"1998","unstructured":"Oldstone, M.B.A. Molecular mimicry and immune-mediated diseases. FASEB J. 12, 1255\u20131265 (1998).","journal-title":"FASEB J."},{"key":"BFnbt2725_CR108","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nature01076","volume":"419","author":"DJ Irvine","year":"2002","unstructured":"Irvine, D.J., Purbhoo, M.A., Krogsgaard, M. & Davis, M.M. Direct observation of ligand recognition by T cells. Nature 419, 845\u2013849 (2002).","journal-title":"Nature"}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nbt.2725.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nbt.2725","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nbt.2725.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:15:52Z","timestamp":1744352152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nbt.2725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":108,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["BFnbt2725"],"URL":"https:\/\/doi.org\/10.1038\/nbt.2725","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"21 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}